Feb 12 (Reuters) - India's Zydus Lifesciences said on Thursday that it and its U.S. unit have agreed to pay $120 million to Astellas Pharma as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder drug Mirabegron.
Zydus and its unit will also pay a pre-paid per‑unit licensing fee on sales of its generic Mirabegron in the U.S. from the date of the agreement until September 2027, the company said.
(Reporting by Hritam Mukherjee in Bengaluru; Editing by Sherry Jacob-Phillips)
